Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a phase II randomized discontinuation trial

Investigational New Drugs

Volumn 29, Issue 3, 2011, Pages 481-488

  Pacey, Simon ^a   Ratain, Mark J ^b   Flaherty, Keith T ^c   Kaye, Stanley B ^a   Cupit, Lisa ^d   Rowinsky, Eric K ^e   Xia, Chenghua ^d   O'Dwyer, Peter J ^c   Judson, I R ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Bayer Pharmaceuticals Corporation   (United States)

^e ImClone Systems   (United States)

Author keywords

Multi targeted kinase inhibitor; Randomized discontinuation trial; Soft tissue sarcoma; Sorafenib (BAY 43 9006)

Indexed keywords

PLACEBO; SORAFENIB;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ARTHRALGIA; ARTICLE; BLEEDING; BLOOD TOXICITY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIAPHORESIS; DIARRHEA; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERTENSION; HYPOALBUMINEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; IMAGE ANALYSIS; LEIOMYOSARCOMA; LIVER DISEASE; LUNG DISEASE; MALE; METABOLIC DISORDER; MULTICENTER STUDY; NAUSEA; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SKIN DISEASE; SKIN TOXICITY; SOFT TISSUE SARCOMA; TUMOR REGRESSION; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; DEMOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PYRIDINES; SARCOMA; SOFT TISSUE NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79955627111     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-009-9367-9     Document Type: Article

References (37)

1. George S (2007) Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor. Curr Oncol Rep 9(4):323-327
2. Siehl J, Thiel E (2007) C-kit, GIST, and imatinib. Recent Results Cancer Res 176:145-151
3. Van GM, van Oosterom AT, Oosterhuis JW et al (1999) Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2, 185 patients treated with anthracycline-containing first-line regimens-a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 17(1):150-157 (Pubitemid 29022388)
4. Nielsen OS, Judson I (2000) van HQ, et al. Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 36(1):61-67 (Pubitemid 30035345)
5. Nielsen OS, Dombernowsky P, Mouridsen H et al (1998) High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group. Br J Cancer 78 (12):1634-1639 (Pubitemid 28550051)
6. Judson I, Radford JA, Harris M et al (2001) Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 37(7):870-877 (Pubitemid 32323965)
7. Benjamin RS, Rouesse J, Bourgeois H, van Hoesel QG (1998) Should patients with advanced sarcomas be treated with chemotherapy? Eur J Cancer 34(7):958-965
8. Penel N, Nisse C, Feddal S, Lartigau E (2001) Epidemiology of soft tissue sarcomas in adults. Presse Med 30(28):1405-1413 (Pubitemid 32952464)
9. Penel N, Nisse C, Feddal S, Lartigau E (2001) Epidemiology of soft tissue sarcomas in adults. Presse Med 30(28):1405-1413 (Pubitemid 32952464)
10. Verweij J, Casali PG, Zalcberg J et al (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364(9440):1127-1134 (Pubitemid 39296599)
11. Talpaz M, Shah NP, Kantarjian H et al (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354(24):2531-2541 (Pubitemid 43882349)
12. Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368(9544):1329-1338 (Pubitemid 44528723)
13. Kasper B, Gil T, D'Hondt V, Gebhart M, Awada A (2007) Novel treatment strategies for soft tissue sarcoma. Crit Rev Oncol Hematol 62(1):9-15 (Pubitemid 46330796)
14. Wilhelm S, Chien DS (2002) BAY 43-9006: preclinical data. Curr Pharm Des 8(25):2255-2257 (Pubitemid 35189898)
15. Wilhelm SM, Carter C, Tang L et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64(19):7099-7109 (Pubitemid 39331023)
16. Strumberg D, Richly H, Hilger RA et al (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23 (5):965-972 (Pubitemid 46202316)
17. Strumberg D, Richly H, Hilger RA et al (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23 (5):965-972 (Pubitemid 46202316)
18. Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2):125-134 (Pubitemid 46089673)
19. Ratain MJ, Eisen T, Stadler WM et al (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24(16):2505-2512 (Pubitemid 46630627)
20. Strumberg D, Richly H, Hilger RA et al (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23 (5):965-972 (Pubitemid 46202316)
21. Llovet JM, Ricci S, Mazzaferro Vet al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378-390
22. Wilhelm SM, Carter C, Tang L et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64(19):7099-7109 (Pubitemid 39331023)
23. Ratain MJ, Eisen T, Stadler WM et al (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24(16):2505-2512 (Pubitemid 46630627)
24. Bos JL (1989) Ras oncogenes in human cancer: a review. Cancer Res 49(17):4682-4689
25. Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949-954 (Pubitemid 34716871)
26. Ratain MJ, Eisen T, Stadler WM et al (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24(16):2505-2512 (Pubitemid 46630627)
27. Ratain MJ, Eisen T, Stadler WM et al (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24(16):2505-2512 (Pubitemid 46630627)
28. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47(1):207-214 (Pubitemid 11167383)
29. Maki RG, D'Adamo DR, Keohan ML et al (2009) Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol May 18
30. Ryan CW, von Mehren M, Rankin CJ et al (2008) Phase II intergroup study of sorafenib (S) in advanced soft tissue sarcomas (STS): SWOG 0505. J Clin Oncol 26:10532
31. Wiebe L, Kasra KE, Maki RG et al (2008) Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): A phase II trial of the University of Chicago Phase II Consortium. J Clin Oncol 26(suppl):10502
32. Reichardt P, Montemurro M, Gelderbloom H et al (2009) Sorafenib fourth-line treatment in imatinib-, sunitinib-, and nilotinib-resistant metastatic GIST: a retrospective analysis. J Clin Oncol 27(15s):10564
33. Tap WD, Federman N, Eilber FC (2007) Targeted therapies for soft-tissue sarcomas. Expert Rev Anticancer Ther 7(5):725-733 (Pubitemid 46805567)
34. Kasper B, Gil T, D'Hondt V, Gebhart M, Awada A (2007) Novel treatment strategies for soft tissue sarcoma. Crit Rev Oncol Hematol 62(1):9-15 (Pubitemid 46330796)
35. Sleifer S, Papai Z, Le CA et al (2007) Phase II study of pazopanib (GW786034) in patients (pts) with relapsed or refractory soft tissue sarcoma (STS): EORTC 62043. J Clin Oncol 25 (18S):10031
36. Heymach JV, Desai J, Manola J et al (2004) Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res 10(17):5732-5740 (Pubitemid 39180949)
37. Guida T, Anaganti S, Provitera L et al (2007) Sorafenib Inhibits Imatinib-Resistant KIT and Platelet-Derived Growth Factor Receptor beta Gatekeeper Mutants. Clin Cancer Res 13 (11):3363-3369 (Pubitemid 46944924)